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Aims Although a true clinical challenge, high bleeding risk patients with an acute coronary syndrome (ACS) undergoing per-
cutaneous coronary intervention (PCI) have never been specifically studied. Leaders Free ACS, a pre-specified Leaders
Free sub-study, determined efficacy, and safety of a combination of 1-month dual anti-platelet therapy (DAPT) with im-
plantation of either a polymer-free Biolimus-A9-coated stent (BA9-DCS) or a bare-metal stent (BMS) in these patients.
Methods
and results
Leaders Free included 2466 patients undergoing PCI who had at least 1 of 13 pre-defined factors for an increased bleed-
ing risk. Of these, 659 ACS patients were included in this analysis (BA9-DCS 330, BMS 329). At 12-month follow-up,
treatment with the BA9-DCS was more effective (clinically driven target-lesion revascularization 3.9 vs. 9.0%,
P ¼ 0.009) and safer (cumulative incidence of cardiac death, myocardial infarction, or definite or probable stent
thrombosis 9.3 vs. 18.5%, P ¼ 0.001), driven by significantly lower rates of cardiac mortality (3.4 vs. 6.9%,
P ¼ 0.049) and myocardial infarction (6.9 vs. 13.8%, P ¼ 0.005).
Conclusion We believe that the results of this sub-analysis from the Leaders Free trial are likely to significantly impact clinical practice
for high bleeding risk patients presenting with an ACS: the use of a BMS can, in our view, no longer be recommended,
and, given the paucity of available data for second-generation DES with shortened DAPT in these patients, the BA9-
DCS should currently be considered as the device with the strongest evidence to support its use for this indication.
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Percutaneous coronary intervention
Introduction
Appropriate and timely antithrombotic therapy is essential for the
outcome of patients presenting with acute coronary syndromes
(ACS). The individual bleeding risk has to be balanced with the is-
chaemic threat. High bleeding risk patients presenting with an
ACS, undergoing percutaneous coronary intervention (PCI), have
never been specifically studied.
For these patients, current guidelines suggest the implantation of
drug-eluting stents (DES) with 3–6 months dual anti-platelet ther-
apy (DAPT) or bare-metal stents (BMS) with 1-month DAPT.1 – 3
Leaders Free ACS is a pre-specified sub-study of Leaders Free4,5
which is a randomized double-blind trial, designed to assess the com-
bination of 1 month of DAPT with either a polymer-free Biolimus-A9-
coated stent (drug-coated stent; DCS) or a BMS in patients with at
least one criterion for an increased bleeding risk such as advanced
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age, oral anticoagulant treatment, recent bleeding, anaemia, chronic
renal failure, or cancer. In this patient group, DCS treatment displayed
superiority not only with respect to clinically driven target-lesion re-
vascularization at 390 days but also regarding the composite safety
endpoint which was the incidence of cardiac death, myocardial infarc-
tion, or definite or probable stent thrombosis.
The aim of this analysis was to focus on the efficacy and safety of a
polymer-free BA9-coated stent with 1-month DAPT in high bleed-
ing risk patients presenting with non-ST-segment-elevation myocar-
dial infarction (NSTEMI) or ST-segment-elevation myocardial
infarction (STEMI).
Methods
Patients and methods
All patients from Leaders Free presenting with STEMI or NSTEMI, under-
going PCI were included. Methods and proceedings for Leaders Free have
been described previously4,5 and are summarized here. Leaders Free is a
randomized, double-blind, clinical trial, which enrolled 2466 patients at
68 sites in 20 countries. Patients were required to meet one or more of
the criteria for an increased bleeding risk listed in Table 1. They were 1:1
randomly assigned to undergo PCI with a polymer-free BA9-DCS (Bio-
freedomTM DCS Biosensors Europe, Morges, Switzerland) or a similar
bare-metal stent (GazelleTM, Biosensors Interventional Technologies,
Singapore). Randomization was performed with the use of either a
Web-based system or a telephone interactive voice-response system
(Merge Healthcare, www.merge.com) in blocks of 16 with no further
stratification. All patients received 1 month of DAPT followed by single
anti-platelet therapy lifelong.
Study proceedings
Percutaneous coronary intervention was performed according to stand-
ard techniques. Vascular access, peri-procedural antithrombotic regi-
men, and lesion preparation were left to the operator. All target
lesions were treated with at least one study stent. Staged procedures
were permitted within 1 week after the index procedure. The protocol
mandated that all patients receive both aspirin and a P2Y12 inhibitor for
30 days, followed by a single anti-platelet agent.
Per protocol patients who were included in the trial because
of planned oral anti-coagulation post-PCI should receive either the
WOEST regimen or triple therapy.
A patient follow-up visit on site was performed at 30 days and 360
days. Further contacts were made at 60 and 120 days. Ischaemia testing
and angiographic evaluation during follow-up were left to the discretion
of the investigator.
Study endpoints
The primary safety endpoint was the cumulative incidence of a compos-
ite of cardiac death, myocardial infarction, or definite or probable stent
thrombosis; the primary efficacy endpoint was the incidence of clinically
driven target-lesion revascularization. Primary endpoint events and
bleeding events were recorded for up to 390 days in order to capture
events occurring soon after the 1-year visit. Myocardial infarction was
defined according to the third universal definition of myocardial infarc-
tion,6 stent thrombosis according to the ARC definitions,7 and bleeding
according to the BARC definitions.8
Clinically driven target-lesion revascularization was defined as PCI or
surgery either for operator-defined restenosis in the treated lesion to-
gether with angina symptoms or documented ischaemia or, for a
core-laboratory-defined restenosis of .70% of the artery diameter
without symptoms or ischaemia.
Statistical analyses
Continuous variables are presented as mean+ SD, categorical data as
counts and percentages. Categorical variables were compared using a x2
test, continuous variables were compared using a two sample t-test.
Whenever appropriate a Fisher exact test was used instead.
For time-to-event variables, hazard ratio or its 95% confidence inter-
val was derived from an unadjusted Cox proportional hazard model.
Cumulative incidence rates come from the Kaplan–Meier estimator
with log-rank P-value to test if the plots differ over time. Proportional
hazard assumptions were checked using Schoenfeld residuals. There
was no adjustment for covariates or imputation for missing data. All
available data were used in the analysis of all endpoints. We performed
additional Cox proportional hazard models to analyze if the DAPT,
P2Y12 inhibitor, or anticoagulant therapy prescription had an impact
on the primary endpoints. The same method was used to analyze the
potential impact of imbalances at baseline. All data were analyzed using
SAS V.9.3 (SAS Institute, Cary, NC, USA).
Results
Patients and procedures
Six hundred and fifty-nine patients in Leaders Free presenting with an
ACS, underwent PCI (Figure 1). Of these, 554 patients had an NSTE-
MI, 105 had an STEMI. 330 were assigned to the BA9-coated DCS
and 329 were assigned to the BMS. Baseline biomarkers and other
patient features are displayed in Table 1.
The patient population was of advanced age and displayed condi-
tions indicative of an increased bleeding risk. Three or more of the
criteria for high bleeding risk were met in 132 patients (20%), 2 cri-
teria in 256 (39%), and only 1 criterion in 271 (41%). The criteria
were well balanced between treatment groups.
Regarding baseline characteristics, there were no significant dif-
ferences except previous stroke, being more frequent in the DCS
group (14.1 vs. 7.9%; P ¼ 0.01), while history of atrial fibrillation
was more frequent in the BMS group (25.5 vs. 33.1%; P ¼ 0.03). Gi-
ven multiple testing across available baseline variables, these findings
are compatible with the play of chance and had no significant impact
on the primary endpoints.
Procedural data are displayed in Table 2. A total of 63.6% of the
procedures in the DCS group and 64.0% in the BMS group were
performed through radial access (P ¼ 0.91). 3.8 and 8.9% of the pro-
cedures in the respective groups were staged (P ¼ 0.01). The latter
had no significant influence on the primary endpoints. 18.7% of the
procedures in the DCS group and 23.0% in the BMS group involved
multi-vessel revascularization (P ¼ 0.16).
Among the 166 patients who were on oral anti-coagulation at
Day 23 post-PCI, data were available for 164 patients. Most patients
(n ¼ 158; 96.3%) received triple therapy and only 6 (3.7%) followed
the WOEST regimen. There was no difference between the treat-
ment groups and no impact on outcomes.
At 23 days, DAPT was used in the DCS and BMS groups in 95.6
and 97.8%, respectively (P ¼ 0.18). In detail, ASA was given in 97.3
and 99.1%, Clopidogrel in 85.0 and 85.2%, Ticagrelor in 11.7 and
11.1%, and Prasugrel in 1.8 and 2.5%. At 37 days, DAPT was
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continued in significantly more patients in the BMS arm (Table 2).
This had no significant effect on the primary endpoints.
Primary endpoints
At 390 days, the primary efficacy endpoint (clinically driven
target-lesion revascularization) had occurred in 12 patients
(3.9%) in the DCS group and 27 patients (9.0%) in the BMS group
(HR 0.41; 95% CI 0.21–0.82; P ¼ 0.009) (Table 3).
At 390 days, the primary safety endpoint (composite of
cardiac death, myocardial infarction, or definite or probable
stent thrombosis) had occurred in 30 patients (9.3%) in the
DCS group and in 59 patients (18.5%) in the BMS group (HR
0.48; 95% CI 0.31–0.75; P ¼ 0.001). The time-to-event curves
for the primary efficacy and safety endpoints are shown in
Figure 2.
Additional analyses
Significant differences between the treatment groups were also ob-
served for cardiac death (DCS 3.4%; BMS 6.9%; HR 0.49; 95% CI
0.23–1.01; P ¼ 0.049 and myocardial infarction (DCS 6.9%; BMS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline patient characteristics and inclusion criteriaa
Drug-coated stent
(N 5 330)
Bare-metal stent
(N5 329)
P-value
Baseline characteristics
Age (years) 76.9+10.0 76.5+9.9 0.17
Female sex 122 (37.0) 110 (33.4) 0.34
Body mass index 26.7+4.8 26.7+4.5 0.98
Diabetes, n/total 111/328 (33.8) 108/329 (32.8) 0.78
Hypertension, n/total 248/330 (75.2) 249/327 (76.1) 0.77
Hypercholesterolaemia 180/322 (55.9) 156/321 (57.9) 0.60
STEMI 57 (17.2) 48 (14.5) 0.40
NSTEMI 273 (82.8) 281 (85.5) 0.40
Creatinine kinase (U/L) 4.14+7.16 3.12+6.40 0.17
Creatinine kinase MB (U/L) 28.19+73.06 16.38+30.10 0.13
High-sensitive troponin (ng/L) 12.77+18.94 13.80+70.18 0.92
Multi-vessel disease 207/327 (64.1) 220/323 (68.1) 0.28
Previous myocardial infarction 63/329 (19.1) 82/329 (24.9) 0.07
Previous PCI 55/330 (16.7) 67/328 (20.4) 0.22
Previous CABG 24/330 (7.3) 23/328 (7.0) 0.90
Congestive heart failure 29/328 (8.8) 43/329 (13.1) 0.08
Atrial fibrillation 84/330 (25.5) 109/329 (33.1) 0.03
Previous stroke 46/326 (14.1) 26/329 (7.9) 0.01
Peripheral vascular disease 47/325 (14.5) 49/328 (14.9) 0.86
Chronic obstructive lung disease 39/330 (11.8) 45/328 (13.7) 0.47
Crusade score 36.4+13.8 36.6+14.1 0.87
Criteria for high risk of bleeding
Oral anti-coagulation planned to continue after PCI 79 (23.9) 101 (30.7) 0.05
Age ≥75 years 232 (70.3) 229 (69.6) 0.85
Haemoglobin ,11 g/L or transfusion within 4 weeks before
randomization
73 (22.1) 79 (24.0) 0.57
Platelet count ,100 000/mm3 4 (1.2) 6 (1.8) 0.57
Hospital admission for bleeding in previous 12 months 23 (7.0) 15 (4.6) 0.18
Stroke in previous 12 months 6 (1.8) 5 (1.5) 0.77
Previous intracerebral bleed 7 (2.1) 7 (2.1) 0.99
Severe chronic liver disease 4 (1.2) 4 (1.2) 0.99
Creatinine clearance ,40 mL/min 62 (18.8) 80 (24.3) 0.08
Cancer (non-skin) in the previous 3 years 35 (10.6) 37 (11.2) 0.79
Planned major surgery in next 12 months 38 (11.5) 36 (10.9) 0.82
Glucocorticoids or NSAID planned for .30 days after PCI 14 (4.2) 12 (3.6) 0.70
Expected non-adherence to .30 days of dual antiplatelet therapy 18 (5.5) 19 (5.8) 0.86
STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-segment myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.
aEither presented as n (%) or mean+ SD.
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13.8%; HR 0.48; 95% CI 0.29–0.81; P ¼ 0.005). There were numer-
ically fewer definite and probable stent thromboses in the DCS
group (1.2 vs. 3.1%; HR 0.39, 95% CI 0.12–1.24; P ¼ 0.099). Rates
of bleeding according to BARC criteria were high and similar in
the two groups (Table 3).
We analyzed if the treatment effects on the primary endpoints
were comparable between patients with and without an ACS and
with NSTEMI or STEMI, respectively. These analyses show that
while the efficacy benefit of the treatment is consistent across all
subgroups, the safety benefit in the Leaders Free population is mainly
driven by the ACS subgroups (Figure 3).
Discussion
At 390 days follow-up, Leaders Free ACS demonstrates that a
polymer-free BA9-coated stent with 1-month DAPT is significantly
more effective and safe than a BMS in high bleeding risk patients pre-
senting with an ACS. The BA9-coated stent not only reduced the
re-intervention rate and the incidence of the composite safety end-
point but also significantly reduced rates of cardiac mortality and
myocardial infarction. These findings were not dependent on the
post-procedural DAPT scheme, the oral anti-coagulation regimen,
or imbalances at baseline.
There are two reasons why patients with an ACS receive pro-
longed DAPT: first for the prevention of secondary events,9 – 12
which is currently recommended for 12 months or beyond after
the event,1 – 3 second for the prevention of stent thrombosis if
they undergo PCI with stent implantation. With stable CAD,
DAPT is currently recommended for at least 4 weeks after
BMS—and 6 months after DES implantation.2,13
The bleeding risk induced by the prolonged DAPT in ACS pa-
tients is usually considered to be more than balanced by the benefits
of a reduction of secondary thrombotic events,14 however, this has
never been specifically studied in ACS patients with an increased risk
of bleeding.15 –18 Current guidelines suggest in this scenario the im-
plantation of a DES with shortened DAPT or a BMS with 1-month
DAPT.1 – 3 The use of BMS for ACS patients increases the rate of
target-lesion revascularization and carries a significant risk for in-
creasing major adverse cardiac events.19,20
The guideline’s recommendations regarding shortening of DAPT
are, besides the results of a network meta-analysis21 mainly based
on the OPTIMIZE22 and RESET23 trials which assessed clinical non-
inferiority of 3 months vs. 12 months of DAPT. The results of both
trials suggest that it may be suitable to shorten DAPT after implant-
ation of a fast-eluting Zotarolimus-eluting DES in selected patients
at low-risk of bleeding, with no detectable benefit, but no significant
trade off regarding clinical events. Observational data from new-
generation Zotarolimus- and Everolimus-eluting stents have also
raised the possibility that DAPT interruption may be safe in selected
low-risk patients.24–26
Figure 1 Leaders Free ACS flow chart.
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Table 2 Procedure details and medicationa
Drug-coated stent (N 5 330) Bare-metal stent (N 5 329) P-value
Procedure details
Radial access 218 (63.6) 231 (64) 0.91
Staged procedure 13 (3.8) 32 (8.9) 0.01
Multi-lesion procedure 113 (32.9) 133 (36.8) 0.28
Multi-vessel procedure 64 (18.7) 83 (23.0) 0.16
LAD 175 (51.0) 193 (53.6) 0.52
LCX 113 (32.9) 114 (31.7) 0.64
LM 8 (2.3) 15 (4.2) 0.16
RCA 110 (32.1) 122 (33.9) 0.17
SVG 5 (1.5) 6 (1.7) 0.93
Bifurcation 43 (12.5) 59 (16.4) 0.15
ISR 5 (1.5) 5 (1.4) 0.94
CTO 26 (7.6) 24 (6.7) 0.64
Mean stent diameter 2.90+0.48 2.90+0.50 0.93
Total stent length 32.20+22.1 33.4+23.3 0.50
Number of stent 1.70+1.0 1.79+1.1 0.27
Lesion success 468 (96.9) 533 (97.4) 0.60
Device success 560 (96.9) 613 (96.7) 0.97
Procedural success 326 (95.0) 341 (94.7) 0.85
Medication
DAPT at Day 23 311 (95.6) 317 (97.8) 0.18
DAPT at Day 37 28 (8.7) 49 (15.2) 0.01
UFH 282 (82.2) 280 (77.6) 0.12
LMWH 28 (8.2) 34 (9.4) 0.56
Bivalirudin 7 (2) 16 (4.4) 0.07
GPIIbIIIa antagonist 7 (2) 5 (1.4)b 0.50
LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCX, right coronary artery; SVG, saphenous vein graft; ISR, in-stent restenosis; CTO, chronic
total occlusion; UFH, unfractionated heparin; LMWH, low-molecular-weight heparin.
aEither presented as n(%) or mean+ SD.
bFollowing the Leaders Free report, medication is reported at Day 23 post-PCI.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Incidence of safety and efficacy endpoints at 390 days, presented as n (%) of patients affected
Endpoint Drug-coated
stent (N 5 330)
Bare-metal
stent (N 5 329)
Hazard ratio
(95% CI)
P-value
Primary safety endpoint: cardiac death, myocardial infarction, or definite/probable
stent thrombosis
30 (9.3) 59 (18.5) 0.48 (0.31–0.75) 0.001
Cardiac death 11 (3.4) 22 (6.9) 0.49 (0.23–1.01) 0.049
Myocardial infarction 22 (6.9) 43 (13.8) 0.48 (0.29–0.81) 0.005
Definite or probable stent thrombosis 4 (1.2) 10 (3.1) 0.39 (0.12–1.24) 0.099
Primary efficacy endpoint: clinically driven TLR 12 (3.9) 27 (9.0) 0.41 (0.21–0.82) 0.009
Bleeding
BARC 1–5 65 (20.2) 67 (21.3) 0.97 (0.69–1.36) 0.86
BARC 2–5 49 (15.2) 54 (17.2) 0.90 (0.61–1.32) 0.60
BARC 3–5 29 (9.0) 29 (9.2) 0.99 (0.59–1.66) 0.99
TLR, target-lesion revascularization; BARC, bleeding according to Academic Research Consortium definition.
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Figure 2 Time-to-event curves for the primary efficacy and safety endpoints *primary efficacy endpoint (clinically driven target-lesion revas-
cularization) **primary safety endpoint (cardiac death, myocardial infarction, or definite and probable stent thrombosis).
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A very recent sub-analysis of the ZEUS trial included patients with
pre-defined risk factors for bleeding. Similar to Leaders Free, this ana-
lysis found a significant disadvantage regarding safety and efficacy in
patients receiving a thin-strut BMS when compared with a
fast-eluting Zotarolimus-eluting stent.27
Despite the fact that patients with a BMS in our analysis had a
higher rate of DAPT use when compared with DCS patients at 37
days, definite and possible stent thrombosis tended to be lower in
the DCS group, while both myocardial infarction and cardiovascular
death were significantly less frequent in the DCS group at follow-up.
The fact that not only the primary efficacy endpoint but also stent
thrombosis and ischaemic events are reduced in the DCS group is
compelling. Spontaneous myocardial infarction (type 1), and myo-
cardial infarction related to stent thrombosis (type 4b), as categor-
ized according to the third Universal Definition of Myocardial
Infarction, occurred significantly less frequent among patients with
a drug-coated stent (see Appendix, Table A1). A comparable, how-
ever, non-significant trend was seen for myocardial infarction re-
lated to in-stent restenosis (type 4c). Because routine angiography
was not systematically performed, it is likely that many of the spon-
taneous myocardial infarctions were also related to in-stent resten-
osis, although this uncertainty does not affect the comparison
between treatment groups.
As demonstrated above, in Leaders Free this superior safety effect
was mainly driven by the ACS subgroups. A similar effect has also
been demonstrated in other studies of BA9 stents. Superior safety
was also observed in the COMFORTABLE AMI study.19 The study,
compared the same drug on the same stent platform as investigated
in this trial, albeit with a biodegradable polymer, with the same BMS
in the setting of acute myocardial infarction. Finally interaction test-
ing in the LEADERS trial28 demonstrated heterogeneity of treat-
ment effects in regards to the primary endpoint in the BA9 STEMI
sub-group.
It is therefore tempting to speculate about a benefit for this type
of therapy in the acute setting that is conferred by BA9. The high li-
pophilicity of this drug which may allow it to penetrate into lipid rich
plaques more effectively than other drugs may explain part of the
superior outcomes in the ACS population. This also means that
our findings may not be extendable to polymer-coated DES or
other polymer-free drug-coated stent designs.
In an ACS population at high risk of bleeding, our data show for
the first time that it is possible to clinically reproduce an efficacy
similar to that of current DES together with a significant safety bene-
fit when compared with BMS implantation with only 1 month DAPT
duration. Of note, despite a course of only 1 month DAPT, the in-
cidence of any reported bleeding events was similar and .20% in
Figure 3 Forest plot of Leaders Free for the primary efficacy and safety endpoints and components by acute coronary syndrome status.
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both groups and the rate of severe bleeding was .9% during the
390 days follow-up. These figures are higher by one order of mag-
nitude than those reported during the first year for several of the
DAPT duration trials,22,23 underlining that a longer course of
DAPT would be expected to be poorly tolerated in this high bleed-
ing risk cohort.
Implications
Although the data presented herein are the result of a sub-analysis
from the Leaders Free trial, and should be, thus, regarded as hypoth-
esis generating, we believe that they are likely to significantly impact
clinical practice for high bleeding risk patients presenting with an
ACS: the use of a BMS can, in our view, no longer be recommended,
and, given the paucity of available data for second-generation DES
with shortened DAPT in these patients, the BA9-DCS should cur-
rently be considered as the device with the strongest evidence to
support its use for this indication.
Limitations
Although pre-defined, Leaders Free ACS is a sub-study of Leaders Free
and was, thus, not powered to detect clinical differences between
the groups.
This pre-defined ACS sub-analysis was not intended to include
unstable angina, since Troponin negative unstable angina was not
thought to be precisely enough defined to serve as discriminator
for an outcome analysis in a randomized trial. Therefore, these pa-
tients were not included in the analysis.
Despite the fact that observed effects tended to be similar in all
groups, the number of STEMI patients in this analysis was limited and
the ACS group consisted mainly of patients with NSTEMI.
In this analysis, we compared the combination of 1 month DAPT
with implantation of a BA9-DCS or with implantation of a BMS only.
Our results cannot be extended to other device or treatment
regimens.
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Table A1 Myocardial infarction stratified by 3rd universial definition of myocardial infarction (6)
Parameter Statistics Drug-coated
stent (N 5 330)
Bare-metal
stent (N 5 329)
Total
(N 5 659)
Hazard ratio P-value
Myocardial infarction n (%) 22 (6.95%) 43 (13.85%) 65 (10.37%) 0.487 (0.291:0.814) 0.005
Myocardial infarction—type 1 n (%) 14 (4.49%) 26 (8.46%) 40 (6.46%) 0.515 (0.269:0.987) 0.04
Myocardial infarction—type 2 n (%) 4 (1.27%) 5 (1.66%) 9 (1.46%) 0.784 (0.211:2.921) 0.72
Myocardial infarction—type 3 n (%) 0 (%) 0 (%) 0 (%) N/A –
Myocardial infarction—type 4a n (%) 5 (1.52%) 6 (1.84%) 11 (1.68%) 0.83 (0.253:2.719) 0.76
Myocardial infarction—type 4b n (%) 0 (0%) 8 (2.52%) 8 (1.26%) N/A 0.004
Myocardial infarction—type 4c n (%) 2 (0.65%) 5 (1.66%) 7 (1.15%) 0.385 (0.075:1.983) 0.24
Myocardial infarction—type 5 n (%) 0 (%) 0 (%) 0 (%) N/A –
Given that many patients did not undergo control angiography when readmitted during follow-up, a definite distinction between Types I, 4b and 4c was sometimes difficult to
establish.
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